Acute liver failure
For patient information click here
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-In-Chief: Husnain Shaukat, M.D [2], Priyamvada Singh, M.B.B.S. [3], Aditya Govindavarjhulla, M.B.B.S. [4]
Synonyms and keywords: ALF, acute hepatic failure, fulminant hepatic failure, fulminant liver failure, fulminant hepatitis
Overview
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Husnain Shaukat, M.D [2]
Overview
Acute liver failure is a sudden and severe loss of liver function with evidence of encephalopathy and coagulopathy with elevated prothrombin time (PT) and (INR) in a person without a preexisting liver disease. The effects of acute liver failure are due to the loss of its metabolic, secretory and regulatory effects. This results in the accumulation of toxic substances which causes deleterious effects. The major pathophysiological mechanisms of morbidity and mortality in patients with acute liver failure are cerebral edema, hypoperfusion to the liver, idiosyncratic drug reactions, depletion of glutathione and viral hepatitis. Acute liver failure may be classified on the basis of the time interval between the onset of symptoms and the development of encephalopathy as hyperacute, acute, subacute, fulminant, subfulminant and late-onset. Acetaminophen toxicity is the most common cause of acute liver failure in the developed world and viral hepatitis (most commonly hepatitis A, hepatitis B and hepatitis E) is most common in the developing world. Acute liver failure must be differentiated from other diseases that cause signs and symptoms of jaundice, coagulopathy, and encephalopathy. The further evaluation should include liver function tests (aspartate aminotransferase [AST], alanine aminotransferase [ALT], alkaline phosphatase, gamma-glutamyl transpeptidase [GGT], total and direct bilirubin, albumin) and prothrombin time/INR. The diagnosis of acute liver failure is made in the presence of coagulopathy (international normalized ratio [INR], >1.5), hepatic encephalopathy and illness duration of fewer than 24 weeks. The commonly used prognostic indicators to predict mortality in patients with acute liver failure and to identify patients who are likely to benefit from liver transplantation include kings college criteria (use for liver transplantation) and model for end-stage liver disease (MELD) score (to predict mortality in patients with chronic and acute liver disease). Common symptoms of acute liver failure include anorexia, malaise, pruritis, bleeding tendencies, confusion, disorientation, and stupor. In the initial stages of acute liver failure, the patient may have mild mental status changes such as altered sleep pattern but may become confused or develop coma in the later stages as the disease progresses. Physical examination of acute liver failure is remarkable for hepatomegaly, right upper quadrant abdominal tenderness, ascites and [[encephalopathy. The management of acute liver failure involves resuscitation of the patient with adequate nutrition and optimization of fluid balance, monitoring and treating the complications and providing nutritional support. The patient should be treated in an appropriate setting preferably a center with liver transplantation facility. Infections and sepsis are common occurrences of fulminant liver failure. The high standards of infection control should be practiced to minimize the nosocomial sepsis. In stage 3 and 4 encephalopathy, intubation and mechanical ventilation are indicated. Acetylcysteine is used for acetaminophen poisoning for up to 72 hours after ingestion. Every effort should be made to seek out the specific cause of acute liver failure since specific treatments are available for some causes of acute liver failure. However, inappropriately prolonged investigations may make surgery impossible because of progression of sepsis and multiorgan failure. The candidates for liver transplantation should be identified as quickly as possible because the progression to multiorgan failure results in deterioration in many patients who are awaiting liver transplantation. While many people who develop acute liver failure recover with supportive treatment, liver transplantation is often required in people who continue to deteriorate or have poor prognostic factors. Effective measures for the primary prevention of acute liver failure include vaccination, proper personal hygiene, maintaining proper body weight, taking precautions while handling needles, blood, body piercing, tattooing and sexual practices. Effective measures for secondary prevention of acute liver failure include management of chronic liver disease and its complications.
Historical Perspective
The hepatic and mental disturbance association dates back to Hippocrates. In the sixteenth century, Ballonius was the first to describe hepatic coma. In 1860, Frerichs described the terminal mental changes in patients with cirrhosis and yellow atrophy of the liver. In 1970, Trey and Davidson introduced the term fulminant hepatic failure. Later it was suggested that the term fulminant should be confined to patients who develop jaundice to encephalopathy within 2 weeks. Terms subfulminant hepatic failure and late-onset hepatic failure were coined for onset between 2 weeks to 3 months and for 8 weeks to 24 weeks respectively. The term of acute liver failure was proposed by King’s college group.
Classification
Acute liver failure may be classified on the basis of the time interval between the onset of symptoms and the development of encephalopathy as hyperacute, acute, subacute, fulminant, subfulminant and late-onset. The different classification systems used are O’Grady system, Bernuau system, and Japanese system. This classification based on time duration provides helpful clues about etiology, complications, and prognosis such as in hyperacute cases, the cause is usually viral infections or acetaminophen toxicity. The subacute cases can be due to idiosyncratic drug reactions and can also be confused with chronic liver disease. The hyperacute liver failure has a better prognosis than subacute liver failure.
Pathophysiology
Acute liver failure is a sudden and severe loss of liver function with evidence of encephalopathy and coagulopathy with elevated prothrombin time (PT) and (INR) in a person without a preexisting liver disease. The effects of acute liver failure are due to the loss of its metabolic, secretory and regulatory effects. This results in the accumulation of toxic substances and causes deleterious effects. The major pathophysiological mechanisms of morbidity and mortality in patients with acute liver failure are cerebral edema, hypoperfusion to the liver, idiosyncratic drug reactions, depletion of glutathione and viral hepatitis. Cerebral edema in acute liver failure can be due to vasogenic and cytotoxic effects. In cytotoxic type, there is intracellular swelling and blood-brain barrier is intact. In vasogenic type, the blood-brain barrier breaks down and plasma and water accumulate in the extracellular space. The increased ammonia concentration in liver failure in combination with the glutamine produced by the astrocytes causes excess levels of glutamine with the help of enzyme glutamine synthetase. The excess glutamine is cytotoxic and can disturb the osmotic gradient which can result in brain swelling. In acute liver failure, the increased levels of nitric oxide in the circulation can also disrupt the cerebral autoregulation. Acetaminophen is the leading cause of acute liver failure in the United States. Acetaminophen causes dose-related toxicity. Toxicity is rarely seen at normal therapeutic doses (up to 4 g/day) without underlying liver disease. Viral hepatitis is the leading cause of acute liver failure in the developing world. Hepatitis A, B, D (associated with B), and E (in endemic countries) are commonly associated with acute liver failure.
Causes
The causes of acute liver failure can be categorized into viral, drugs and toxins, vascular and metabolic. Common causes of acute liver failure include acetaminophen toxicity, viral hepatitis (most commonly hepatitis A, hepatitis B and hepatitis E), alcoholic hepatitis, autoimmune, sepsis, right heart failure and idiopathic. Acetaminophen toxicity is the most common cause of acute liver failure in the developed world and viral hepatitis (most commonly hepatitis A, hepatitis B and hepatitis E) is most common in the developing world.
Differentiating Acute liver failure from other Diseases
Acute liver failure must be differentiated from other diseases that cause signs and symptoms of jaundice, coagulopathy, and encephalopathy. The differentials include acute hepatitis, cholestatic jaundice, and hemolytic jaundice. The common causes of acute hepatitis causing acute liver failure include acetaminophen toxicity, viral hepatitis, alcoholic hepatitis, autoimmune hepatitis, acute fatty liver of pregnancy, Wilson’s disease, ischemic hepatitis and hepatic congestion due to right heart failure and Budd–chiari syndrome.
Epidemiology and Demographics
The incidence of acute liver failure in the United States is 2000-2300 cases annually. In the year 2009, the diagnosis of acute hepatic necrosis was 420 cases per 100,000 cases of all adult liver transplants in the United States. In the year 1998 to 2008, according to the United States acute liver failure (ALF) registry statistics, the most common cause of acute liver failure was acetaminophen with 46000 cases per 100,000 individuals and 12000 cases per 100,000 individuals for other drugs. Acute hepatitis B is the cause of acute liver failure in 1000 individuals per 100,000 individuals but it increases to 20,000 individuals per 100,000 individuals with hepatitis D virus co-infection. Acute liver failure is more common in women than men, and women with acute liver failure were older than men. Women are more commonly affected with autoimmune hepatitis and hepatitis E viral infection than men. The acute liver failure is seen more in the white population with 74,000 individuals per 100,000 individuals, 10,000 individuals per 100,000 individuals in the Hispanics, 3000 individuals per 100,000 individuals in the Black population and 5000 individuals per 100,000 individuals in the Asian population. The most common cause of acute liver failure in the developing countries is viral infection mainly hepatitis A and hepatitis B. The most common cause of acute liver failure in the developed world is acetaminophen toxicity. The acute liver failure secondary to hepatitis B is also on the rise in the developed world due to immigration.
Risk Factors
The risk factors in the development of acute liver failure can be categorized into viral, drugs and toxins, vascular, metabolic and systemic illnesses. Common risk factors of acute liver failure include acetaminophen toxicity, viral hepatitis (most commonly hepatitis A, hepatitis B and hepatitis E), alcoholic hepatitis, autoimmune hepatitis, sepsis, heart failure, renal failure, immunocompromised state, older age and malnourishment. Acetaminophen toxicity is the most common risk factor of acute liver failure in the developed world and viral hepatitis (most commonly hepatitis A, hepatitis B and hepatitis E) is most common in the developing world.
Screening
There is insufficient evidence to recommend routine screening for an acute liver failure.
Natural History, Complications and Prognosis
Acute liver failure is a sudden and severe loss of liver function with evidence of encephalopathy and coagulopathy with elevated prothrombin time (PT) and (INR) in a person without the preexisting liver disease. The commonly used time duration for an acute liver disease is < 26 weeks. Acute liver failure can be hyperacute, acute or subacute depending upon how long the patient has signs and symptoms of liver failure. If left untreated, patients with acute liver failure can eventually progress to develop confusion, comatose state, and death. Common complications of acute liver failure are hepatic encephalopathy, cerebral edema, coagulopathy, a systemic inflammatory response syndrome, acute renal failure and acute pulmonary failure. The important factors in determining the prognosis of acute liver failure include patients’ age, the severity of encephalopathy and the underlying cause of acute liver failure. The commonly used prognostic indicators to predict mortality in patients with acute liver failure and to identify patients who are likely to benefit from liver transplantation include kings college criteria ( use for liver transplantation ) and model for end-stage liver disease (MELD) score (to predict mortality in patients with chronic and acute liver disease).
Diagnosis
Acute liver failure is a sudden loss of hepatic function in a patient without any evidence of underlying liver disease. Acute liver failure should be suspected in a patient with mental status changes, jaundice, and right upper quadrant pain or nonspecific symptoms such as malaise, nausea and fatigue of fewer than 26 weeks. The further evaluation should include liver function tests (aspartate aminotransferase [AST], alanine aminotransferase [ALT], alkaline phosphatase, gamma-glutamyl transpeptidase [GGT], total and direct bilirubin, albumin) and prothrombin time/INR. The diagnosis of acute liver failure is made in the presence of coagulopathy (international normalized ratio [INR], >1.5), hepatic encephalopathy and illness duration of fewer than 24 weeks.
Diagnostic Criteria
Acute liver failure is a sudden loss of hepatic function in a patient without any evidence of underlying liver disease. The diagnosis of acute liver failure is made in the presence of coagulopathy (international normalized ratio [INR], >1.5), hepatic encephalopathy and illness duration of fewer than 24 weeks.
History and Symptoms
Obtaining the focused history is an important aspect of making a diagnosis of an acute liver failure. It provides insight into the cause, precipitating factors, prognosis and the correct therapy. Specific areas of focus when obtaining a history from the patient include timing of the onset of jaundice, alcohol intake, medications, family history, risk factors of viral hepatitis and past medical history. Common symptoms of acute liver failure include anorexia, malaise, pruritis, bleeding tendencies, confusion, disorientation, and stupor.
Physical Examination
Patients with acute liver failure may appear lethargic, anorexic and fatigue. In the initial stages of acute liver failure, the patient may have mild mental status changes such as altered sleep pattern but may become confused or develop coma in the later stages as the disease progresses. Physical examination of acute liver failure is remarkable for hepatomegaly, right upper quadrant abdominal tenderness, ascites and encephalopathy.
Laboratory Findings
Acute liver failure can present with nonspecific symptoms and it occurs in healthy individuals without a previous history of liver disease. So, the initial labs in the acute liver failure are planned to evaluate both the etiology and the severity of the disease. All patients with clinical or laboratory evidence of moderate to severe acute hepatitis should have an immediate measurement of prothrombin time and careful evaluation of mental status. If the prothrombin time is prolonged (INR ≥1.5) and there is any evidence of altered sensorium, the diagnosis of acute liver failure should be strongly suspected and hospital admission is mandatory.
Imaging Findings
There are no chest x-ray findings associated with acute liver failure. Computed tomography (CT) scanning can also be done in the workup of acute liver failure especially when the ultrasound is not very sensitive as in case of obese patients and massive ascites. CT scan of the head can be done to exclude other causes of altered mental status such as brain abscess or intracranial mass lesions as well as cerebral edema which is a complication of acute liver failure. Acute liver failure can be accompanied by renal failure. Intravenous contrast used with CT scan can further aggravate renal failure. An ultrasound of the liver can be done in the workup of acute liver failure to evaluate ascites and other causes of hepatic failure. It can also assist in the evaluation of intrahepatic mass, abscess, cirrhosis, and malignancy. A doppler ultrasonography can also evaluate the flow and patency of hepatic vessels (hepatic vein and hepatic artery) to rule out Budd-Chiari syndrome, hepatic congestion, and portal hypertension. In a patient with acute liver failure secondary to hepatic ischemia (elevated transaminases), an echocardiogram can be used to identify the etiology if history, labs and other imaging studies do not identify the cause of hepatic ischemia.
Other Diagnostic Studies
Liver biopsy can be used to identify the definite etiology of acute liver failure. A percutaneous liver biopsy is often contraindicated due to the risk of coagulopathy and overt bleeding. The transjugular liver biopsy is helpful in the workup of acute liver failure if there is a risk of bleeding and findings of biopsy depends on the etiology of the acute liver failure. Liver biopsy can identify the definite cause of acute liver failure such as Wilson disease, autoimmune hepatitis, malignant infiltration or acute fatty liver of pregnancy.
Treatment
Medical Therapy
The management of acute liver failure involves resuscitation of the patient with adequate nutrition and optimization of fluid balance, monitoring and treating the complications and providing nutritional support. The patient should be treated in an appropriate setting preferably a center with liver transplantation facility. Infections and sepsis are common occurrences of fulminant liver failure. The high standards of infection control should be practiced to minimize the nosocomial sepsis. The diagnosis of hepatic injury in hyperacute cases can be a challenge as jaundice can be minimal during that period and confusion or agitation may be the dominant findings. In acute liver failure, the sedative medications should be used with caution as they may mask the worsening encephalopathy and the hepatic clearance may be decreased which can aggravate the sedative effect. However, the short-acting benzodiazepines in low dose can be used during agitation. In acute liver failure patients, opioids are avoided as they decrease the seizure threshold. H2 receptor blockers and proton pump inhibitors are indicated to prevent and treat stress gastropathy. In stage 3 and 4 encephalopathy, intubation and mechanical ventilation are indicated. Acetylcysteine is used for acetaminophen poisoning for up to 72 hours after ingestion. It can dramatically improve the outcome if administered within eight hours of acetaminophen ingestion. The patients with acute liver failure may not have a clear history of acetaminophen intake. Therefore, the threshold for administering acetylcysteine should be low and can also be administered in an acute liver failure of unknown etiology. Every effort should be made to seek out the specific cause of acute liver failure since specific treatments are available for some causes of acute liver failure. However, inappropriately prolonged investigations may make surgery impossible because of progression of sepsis and multiorgan failure.
Surgery
The candidates for liver transplantation should be identified as quickly as possible because the progression to multiorgan failure results in deterioration in many patients who are awaiting liver transplantation. While many people who develop acute liver failure recover with supportive treatment, liver transplantation is often required in people who continue to deteriorate or have poor prognostic factors. The patient’s candidacy for liver transplantation should be assessed based on the patient’s clinical scenario, as well as upon social and financial factors. Patient evaluation for liver transplantation should be done as soon as possible and before encephalopathy occurs. The key common feature among various prognostic evaluation systems is the presence of encephalopathy. Other common features are patient’s age and severity of the liver injury which is assessed by coagulopathy or jaundice. To address the limitations, a wide variety of prognostic systems have been proposed but none has universal acceptance. King’s college criteria is the most well-characterized evaluation system. Common absolute contraindications for liver transplantation include untreated sepsis, uncontrolled extrahepatobillary infection, alcohol abuse, uncontrolled cardiopulmonary disease, cholangiocarcinoma, metastatic malignancy to the liver and life-threatening systemic illness. Common postoperative complications for liver transplantation include infections, graft failure, vascular compromise, biliary stricture or stenosis, anastomosis leakage, thrombosis of hepatic artery and portal vein and depression.
Primary Prevention
Effective measures for the primary prevention of acute liver failure include vaccination, proper personal hygiene, maintaining proper body weight, taking precautions while handling needles, blood, body piercing, tattooing and sexual practices.
Secondary Prevention
Effective measures for secondary prevention of acute liver failure include management of chronic liver disease and its complications. In patients with resolved hepatitis B infection, antiviral prophylaxis can be considered in the patients who have a risk of reactivation such as during increasing levels of immunosuppression.
References
Historical Perspective
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Husnain Shaukat, M.D [2]
Overview
The association of hepatic and mental disturbance dates back to Hippocrates. In the sixteenth century, Ballonius was the first to describe hepatic coma. In 1860, Frerichs described the terminal mental changes in patients with cirrhosis and yellow atrophy of the liver. In 1970, Trey and Davidson introduced the term fulminant hepatic failure. Later it was suggested that the term fulminant should be confined to patients who develop jaundice to encephalopathy within 2 weeks. Terms subfulminant hepatic failure and late-onset hepatic failure were coined for onset between 2 weeks to 3 months and for 8 weeks to 24 weeks respectively. The term of acute liver failure was proposed by King’s college group.
Historical Perspective
- The hepatic and mental disturbance association dates back to Hippocrates ( about 460 – 375 B.C.).[1][2]
- In the sixteenth century, Ballonius was the first to describe hepatic coma.
- In 1660, Franciscus Rubeus and in 1725, Jacobus Vercellonius described liver failure further.
- Wickham Legg wrote a comprehensive review on acute liver atrophy in his book on liver diseases.
- In 1860, Frerichs described the terminal mental changes in patients with cirrhosis and yellow atrophy of the liver.
- The concept of inflammatory process was first described by Bright.[1]
- In 1970, Trey and Davidson introduced the term fulminant hepatic failure.
- Horaczek’s monograph contained several entities which he called bilious dyscrasia’s. The more severe forms corresponds closely with hepatic coma and anatomically with acute yellow atrophy.
- Later it was suggested that the term fulminant should be confined to patients who develop jaundice to encephalopathy within 2 weeks. Terms subfulminant hepatic failure and late onset hepatic failure were coined for onset between 2 weeks to 3 months and for 8 weeks to 24 weeks respectively.[3][4]
- The term of acute liver failure was proposed by Kings college group.[5]
References
- ↑ 1.0 1.1 Kadam PD, Chuan HH (2016). “Erratum to: Rectocutaneous fistula with transmigration of the suture: a rare delayed complication of vault fixation with the sacrospinous ligament”. Int Urogynecol J. 27 (3): 505. doi:10.1007/s00192-016-2952-5. PMID 26811110.
- ↑ Trey C, Davidson CS (1970). “The management of fulminant hepatic failure”. Progress in liver diseases. 3: 282–98. PMID 4908702.
- ↑ Bernuau J, Goudeau A, Poynard T; et al. (1986). “Multivariate analysis of prognostic factors in fulminant hepatitis B”. Hepatology. 6 (4): 648–51. PMID 3732998.
- ↑ Gimson AE, O’Grady J, Ede RJ, Portmann B, Williams R (1986). “Late onset hepatic failure: clinical, serological and histological features”. Hepatology. 6 (2): 288–94. PMID 3082735.
- ↑ Sass DA, Shakil AO (2005). “Fulminant hepatic failure”. Liver Transpl. 11 (6): 594–605. doi:10.1002/lt.20435. PMID 15915484.
Classification
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Husnain Shaukat, M.D [2] Aditya Govindavarjhulla, M.B.B.S. [3]
Overview
Acute liver failure may be classified on the basis of the time interval between the onset of symptoms and the development of encephalopathy as hyperacute, acute, subacute, fulminant, subfulminant and late-onset. The different classification systems used are O’Grady system, Bernuau system, and Japanese system. This classification based on time duration provides helpful clues about etiology, complications, and prognosis such as in hyperacute cases, the cause is usually viral infections or acetaminophen toxicity. The subacute cases can be due to idiosyncratic drug reactions and can also be confused with chronic liver disease. The hyperacute liver failure has a better prognosis than subacute liver failure.
Classification
Acute liver failure may be classified on the basis of the duration of the symptoms between the onset of jaundice to the onset of encephalopathy. The different classification systems based on the number of weeks from the appearance of jaundice to the encephalopathy are:[1][2][3][4][5][6]
| Classification system | Duration |
|---|---|
| O’Grady System |
|
| Bernuau System |
|
| Japanese System |
|
- This classification based on time duration provides helpful clues about etiology, complications, and prognosis such as in hyperacute cases, the cause is usually viral infections or acetaminophen toxicity.
- The subacute cases can be due to idiosyncratic drug reactions and can also be confused with chronic liver disease.
- The hyperacute liver failure has a better prognosis than subacute liver failure.
Classification based on etiology
There is no established classification of acute liver failure on the basis of etiology. However, it can be classified on the basis of etiology as:[7][8]
Viral
- The viruses associated with hepatitis are hepatitis A, B, C, D, E, cytomegalovirus (CMV), varicella, herpes simplex virus (HSV) and adenovirus.
Metabolic
Vascular
Drugs and Toxins
Other
References
- ↑ O’Grady JG, Schalm SW, Williams R. Acute liver failure: redefining the syndromes. Lancet 1993;342:273-5. PMID 8101303.
- ↑ O’Grady JG (2005). “Acute liver failure”. Postgraduate medical journal. 81 (953): 148–54. doi:10.1136/pgmj.2004.026005. PMID 15749789.
- ↑ Williams R (1996). “Classification, etiology, and considerations of outcome in acute liver failure”. Semin Liver Dis. 16 (4): 343–8. doi:10.1055/s-2007-1007247. PMID 9027947.
- ↑ O’Grady JG, Schalm SW, Williams R (1993). “Acute liver failure: redefining the syndromes”. Lancet. 342 (8866): 273–5. PMID 8101303.
- ↑ Bernuau J, Rueff B, Benhamou JP (1986). “Fulminant and subfulminant liver failure: definitions and causes”. Semin Liver Dis. 6 (2): 97–106. doi:10.1055/s-2008-1040593. PMID 3529410.
- ↑ Mochida S, Nakayama N, Matsui A, Nagoshi S, Fujiwara K (2008). “Re-evaluation of the Guideline published by the Acute Liver Failure Study Group of Japan in 1996 to determine the indications of liver transplantation in patients with fulminant hepatitis”. Hepatol Res. 38 (10): 970–9. doi:10.1111/j.1872-034X.2008.00368.x. PMID 18462374.
- ↑ Lee WM, Squires RH, Nyberg SL, Doo E, Hoofnagle JH (2008). “Acute liver failure: Summary of a workshop”. Hepatology. 47 (4): 1401–15. doi:10.1002/hep.22177. PMC 3381946. PMID 18318440.
- ↑ Lee WM (2008). “Etiologies of acute liver failure”. Semin. Liver Dis. 28 (2): 142–52. doi:10.1055/s-2008-1073114. PMID 18452114.
Pathophysiology
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [2] Associate Editor(s)-in-Chief: Aditya Govindavarjhulla, M.B.B.S. [3] Husnain Shaukat, M.D [4]
Overview
Acute liver failure is a sudden and severe loss of liver function with evidence of encephalopathy and coagulopathy with elevated prothrombin time (PT) and (INR) in a person without a preexisting liver disease. The consequences of acute liver failure are due to the loss of its metabolic, secretory and regulatory effects. This results in the accumulation of toxic substances and causes deleterious effects. The major pathophysiological mechanisms of morbidity and mortality in patients with acute liver failure are cerebral edema, hypoperfusion to the liver, idiosyncratic drug reactions, depletion of glutathione and viral hepatitis. Cerebral edema in acute liver failure can be due to vasogenic and cytotoxic effects. In cytotoxic type, there is intracellular swelling but blood-brain barrier is intact. In vasogenic type, the blood-brain barrier breaks down and plasma and water accumulate in the extracellular space. The increased ammonia concentration in liver failure in combination with the glutamine produced by the astrocytes causes excess levels of glutamine with the help of enzyme glutamine synthetase. The excess glutamine is cytotoxic and may influence the osmotic gradient which could result in brain edema. In acute liver failure, the increased levels of nitric oxide in the circulation can also disrupt the cerebral autoregulation. Acetaminophen is the leading cause of acute liver failure in the United States. Acetaminophen causes dose-related toxicity. Toxicity is rarely seen at normal therapeutic doses (up to 4 g/day) without underlying liver disease. Viral hepatitis is the leading cause of acute liver failure in the developing world. Hepatitis A, B, D (associated with B), and E (in endemic countries) are commonly associated with acute liver failure.
Pathophysiology
Acute liver failure is a sudden and severe loss of liver function with evidence of encephalopathy and coagulopathy with elevated prothrombin time (PT) and (INR) in a person without preexisting liver disease.
- The effects of acute liver failure are due to the loss of its metabolic, secretory and regulatory effects. This results in the accumulation of toxic substances and causes deleterious effects.
- The major pathophysiological mechanisms of morbidity and mortality in patients with acute liver failure are cerebral edema, hypoperfusion to the liver, idiosyncratic drug reactions, depletion of glutathione, and viral hepatitis.
- Cerebral edema in acute liver failure can be due to vasogenic and cytotoxic effects.
- In cytotoxic type, there is intracellular swelling but blood-brain barrier is intact.
- In vasogenic type, the blood-brain barrier breaks down and plasma and water accumulate in the extracellular space.
- The increased ammonia concentration in liver failure in combination with the glutamine produced by the astrocytes causes excess levels of glutamine with the help of enzyme glutamine synthetase. The excess glutamine is cytotoxic and can disturb the osmotic gradient which can result in brain edema.
- In acute liver failure, the increased levels of nitric oxide in the circulation can also disrupt the cerebral autoregulation.
Specific Conditions
Acetaminophen Toxicity
- Acetaminophen is the leading cause of acute liver failure in the United States.
- Acetaminophen causes dose-related toxicity.
- Toxicity is rarely seen at normal therapeutic doses (up to 4 g/day) without underlying liver disease.
- Acetaminophen is mainly metabolized (90 %) in the liver and its metabolic end products (sulfate and glucuronide conjugates) are then excreted in the urine.
- Remaining one half unmetabolized acetaminophen is excreted unchanged in the urine and rest is metabolized by cytochrome P450 pathway to N-acetyl-p-benzoquinoneimine (NAPQI).
- NAPQI is hepatotoxic and converted to nontoxic cysteine and mercaptan compounds by hepatic glutathione which are then excreted in the urine.
- At toxic doses, the sulfate and glucuronide conjugation pathway are overwhelmed and led to increased acetaminophen to be metabolized by cytochrome P450.
- At toxic doses, the glutathione stores are depleted and it led to excess unattended NAPQI which causes hepatotoxicity.
Other Drugs
- Drugs other than acetaminophen also cause acute liver failure.
- These constitute 13% of cases of acute liver failure in US.[1]
- They cause idiosyncratic drug hepatotoxicity.
- They usually present within six months of drug initiation.
Mushroom Poisoning
- This is mainly caused by the genus Amanita (Amanita phalloides).[2]
- Presentations may vary from case to case and it constitutes a medical emergency.
- Patients may recover from traditional medical treatment, or may require transplantation in more severe cases.
Viral Hepatitis
- Hepatitis A, B, D (associated with B), and E (in endemic countries) can cause acute liver failure in the developing world.
- Viral hepatitis (Hepatitis A and B) constitute to causing 12% of the cases of acute liver failure in US.[1]
- Hepatitis C alone doesn’t seem to cause acute liver failure.[3]
- There is a difference in the survival rate of patients with acute liver failure in hepatitis A and hepatitis B. This may be an inherent feature of infections and does not depend on the severity of dysfunction.[3]
Autoimmune Hepatitis
- Autoimmune hepatitis may be an unrecognized coexistent condition.
- Autoantibodies are helpful in the diagnosis of the condition. In cases of a negative test for autoantibodies, biopsy may be required.
- A few patients may need transplantation along with steroid therapy.
Ischemic Injury
- This condition is called shock liver. It is a common occurrence in the ICU with a prevalence of 10%.[4]
- Shock liver results from severe hypotension due to any causes such as heart failure or vasoconstictive drugs.
- Early recovery frequently occurs, but the long term outcome depends on the underlying cause of the ischemia.
HELLP Syndrome
- Some women near the end of their pregnancy may develop rapidly progressive liver failure.
- HELLP syndrome conisists of the triad of hemolysis, elevated liver enzymes and low platelets.
- Most of the patients will improve spontaneously with delivery.
- Postpartum deterioration may require liver transplantation.
Malignancy
- Malignant infiltration may cause acute liver failure.
- Severe acute infiltrations may occur with a few malignancies like breast cancer, small cell lung cancer, lymphoma, melanoma, and myeloma.
- Transplantation is not advised in these patients.[5]
Gross Pathology
On gross pathology, characteristic findings of acute liver failure include:
Microscopic Pathology
On microscopic pathology, characteristic findings of acute liver failure include:[6]

Soource:By Nephron (Own work) [CC BY-SA 3.0 (https://creativecommons.org/licenses/by-sa/3.0) or GFDL (http://www.gnu.org/copyleft/fdl.html)], via Wikimedia Commons
{{#ev:youtube|G5G9AnVhqhI}}
{{#ev:youtube|l4m3f2KCxLM}}
References
- ↑ 1.0 1.1 Ostapowicz G, Fontana RJ, Schiødt FV, Larson A, Davern TJ, Han SH, McCashland TM, Shakil AO, Hay JE, Hynan L, Crippin JS, Blei AT, Samuel G, Reisch J, Lee WM (2002). “Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States”. Annals of Internal Medicine. 137 (12): 947–54. PMID 12484709. Retrieved 2012-10-27. Unknown parameter
|month=ignored (help) - ↑ Catalina MV, Núñez O, Ponferrada A, Menchén L, Matilla A, Clemente G, Bañares R (2003). “[Liver failure due to mushroom poisoning: clinical course and new treatment perspectives]”. Gastroenterología Y Hepatología (in Spanish; Castilian). 26 (7): 417–20. PMID 12887855. Retrieved 2012-10-27.
- ↑ 3.0 3.1 Schiødt FV, Davern TJ, Shakil AO, McGuire B, Samuel G, Lee WM (2003). “Viral hepatitis-related acute liver failure”. The American Journal of Gastroenterology. 98 (2): 448–53. doi:10.1111/j.1572-0241.2003.t01-1-07223.x. PMID 12591067. Retrieved 2012-10-27. Unknown parameter
|month=ignored (help) - ↑ Fuhrmann V, Jäger B, Zubkova A, Drolz A (2010). “Hypoxic hepatitis – epidemiology, pathophysiology and clinical management”. Wiener Klinische Wochenschrift. 122 (5–6): 129–39. doi:10.1007/s00508-010-1357-6. PMID 20361374. Retrieved 2012-10-27. Unknown parameter
|month=ignored (help) - ↑ Woolf GM, Petrovic LM, Rojter SE, Villamil FG, Makowka L, Podesta LG, Sher LS, Memsic L, Vierling JM (1994). “Acute liver failure due to lymphoma. A diagnostic concern when considering liver transplantation”. Digestive Diseases and Sciences. 39 (6): 1351–8. PMID 8200270. Unknown parameter
|month=ignored (help);|access-date=requires|url=(help) - ↑ [1]
Causes
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Husnain Shaukat, M.D [2]
Overview
The causes of acute liver failure can be categorized into viral, drugs and toxins, vascular, and metabolic. Common causes of acute liver failure include acetaminophen toxicity, viral hepatitis (most commonly hepatitis A, hepatitis B and hepatitis E), alcoholic hepatitis, autoimmune, sepsis, right heart failure, and idiopathic. Acetaminophen toxicity is the most common cause of acute liver failure in the developed world and viral hepatitis (most commonly hepatitis A, hepatitis B and hepatitis E) is most common in the developing world.
Causes
Common Causes
The common causes of acute liver failure are:[1][2][3][4][2][5]
- Acetaminophen overdose, the reason is usually suicidal intent. Additionally, the toxic threshold dose of acetaminophen decreases in some cases, such as in chronic alcoholics, diabetics, and while fasting. Drug-induced acute liver failure is the most common cause in the developed world. It is responsible for more than 50% of the cases of acute liver failure in the United States.
- Idiosyncratic reactions to medications such as tetracycline, troglitazone, antituberculosis drugs, and anti-epileptic drugs
- Viral hepatitis (hepatitis A, B and hepatitis E) are the most common. The incidence of acute liver failure in post-viral hepatitis has decreased due to the vaccination and improved sanitation in the developed world. However, it is still the most common cause in the developing world.
- Alcohol
- Autoimmune hepatitis
- Acute fatty liver of pregnancy
- Reye syndrome
- Wilson’s disease
- Idiopathic (without an obvious cause)
- Diseases of fatty acid oxidation pathways
- Parvovirus B19 infection
- Budd–Chiari syndrome
- Malignancy such as lymphomas
- Shock
- Sepsis
- Hyperthermia
- Hypothermia
- HELP syndrome
Causes by Organ System
Causes in Alphabetical Order
- 8-Hyydroxyquinoline
- Abacavir
- Acetaminophen
- Acute fatty liver of pregnancy
- Adenovirus
- Adult onset Still’s disease
- Alcohol
- Allopurinol
- Alpha1-antitrypsin deficiency
- Amanita phalloides
- Amatoxins
- Amiodarone
- Amitriptyline
- Amoxicillin-clavulanate
- Ampicillin
- Anticonvulsants
- Antituberculosis drugs
- Asphyxia
- Aspirin
- Atorvastatin
- Autoimmune hepatitis
- Bacillus cereus
- Bromfenac
- Budd-Chiari syndrome
- Carbamazepine
- Carbon tetrachloride
- Cardiomyopathy
- Carnitine palmitoyltransferase 1 deficiency
- Chaparral
- Chelidonium
- Ciprofloxacin
- Cirrhosis
- Cocaine
- Comfrey
- Congestive heart failure
- Cryptogenic
- Cyanobacteria
- Cyclophosphamide
- Cytomegalovirus
- Dantrolene
- Dapsone
- Didanosine
- Dideoxyinosine
- Disulfiram
- Doxycycline
- Echovirus
- Ecstacy
- Efavirenz
- Ephedra
- Epstein-Barr virus
- Erlotinib
- Erythromycin
- Ethanol
- Etodolac
- Extracorporeal membrane oxygenation
- Fasciola hepatica
- Fatty acid oxidation pathway diseases
- Fluoroquinolones
- Flutamide
- Fructose intolerance
- Galactosemia
- Gemtuzumab
- Gemtuzumab
- Germander tea
- Ginseng
- Gold
- Graft versus host disease
- Gyromitrin
- Halothane
- He Shou Wu
- Heart surgery
- Heat stroke
- HELLP syndrome
- Hemochromatosis
- Hemosiderosis
- Hepatectomy
- Hepatic arterial thrombosis
- Hepatic veno-occlusive disease
- Hepatitis A
- Hepatitis B
- Hepatitis C
- Hepatitis D
- Herpes simplex
- Hyperthermia
- Hypoplastic left heart syndrome
- Hypotension
- Hypothermia
- Imipramine
- Interferon beta
- Iron compounds
- Ischemic hepatitis
- Isoflurane
- Isoniazid
- Ixabepilone
- Kava kava
- Ketoconazole
- Labetalol
- LCAT deficiency
- Leflunomide
- Leptospirosis
- Leukemia
- Liver tumor
- Loratadine
- Lovastatin
- Ma Huang
- MAO inhibitors
- Meloxicam
- Methotrexate
- Methyldopa
- Moxifloxacin
- Mushroom poisoning
- Myocarditis
- Nevirapine
- Niacin
- Nicotinic acid
- Nitisinone
- Nitrofurantoin
- Non A non B hepatitis
- Nortriptyline
- NSAIDs
- Oral contraceptive pills
- Parainfluenza viruses
- Parvovirus
- Pazopanib
- Pemoline
- Pennyroyal
- Phenytoin
- Portal vein thrombosis
- Propylthiouracil
- Pyrazinamide
- Regorafenib
- Reye’s syndrome
- Rifampin
- Senecio
- Sepsis
- Shock
- Sickle cell disease
- Simvastatin
- Skull cap
- Statins
- Sulfasalazine
- Suloctidil
- Terbinafine
- Tetracycline
- Teucrium polium
- Tolcapone
- Toluene
- Tricyclic antidepressants
- Troglitazone
- Tyrosinemia
- Valproic acid
- Viral hemorrhagic fever
- Viral hepatitis
- Visceral leishmaniasis
- Wilson’s disease
- Yellow phosphorous
References
- ↑ Ichai P, Samuel D (2008). “Etiology and prognosis of fulminant hepatitis in adults”. Liver Transpl. 14 Suppl 2: S67–79. doi:10.1002/lt.21612. PMID 18825677.
- ↑ 2.0 2.1 Ostapowicz G, Fontana RJ, Schiødt FV, Larson A, Davern TJ, Han SH, McCashland TM, Shakil AO, Hay JE, Hynan L, Crippin JS, Blei AT, Samuel G, Reisch J, Lee WM (2002). “Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States”. Ann. Intern. Med. 137 (12): 947–54. PMID 12484709.
- ↑ Hoofnagle JH, Nelson KE, Purcell RH (2012). “Hepatitis E.” N Engl J Med. 367 (13): 1237–44. doi:10.1056/NEJMra1204512. PMID 23013075.
- ↑ Wasley A, Fiore A, Bell BP (2006). “Hepatitis A in the era of vaccination”. Epidemiol Rev. 28: 101–11. doi:10.1093/epirev/mxj012. PMID 16775039.
- ↑ Björnsson E, Olsson R (2005). “Outcome and prognostic markers in severe drug-induced liver disease”. Hepatology. 42 (2): 481–9. doi:10.1002/hep.20800. PMID 16025496.
Differentiating Acute Liver Failure from other Diseases

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Husnain Shaukat, M.D [2]
Overview
Acute liver failure must be differentiated from other diseases that cause signs and symptoms of jaundice, coagulopathy, and encephalopathy. The differentials include acute hepatitis, cholestatic jaundice, and hemolytic jaundice. The common causes of acute hepatitis causing acute liver failure include acetaminophen toxicity, viral hepatitis, alcoholic hepatitis, autoimmune hepatitis, acute fatty liver of pregnancy, Wilson’s disease, ischemic hepatitis and hepatic congestion due to right heart failure and Budd–chiari syndrome.
Differentiating Acute Liver Failure from other Diseases
Acute liver failure must be differentiated from other diseases that cause signs and symptoms of jaundice, coagulopathy, and encephalopathy.[1][2][3][4]
| Condition | Differentiating signs and symtoms | Differentiating Tests |
|---|---|---|
| Acute hepatits |
|
|
| Cholestasis |
|
|
| Hemolysis |
|
|
Abbreviations:
RUQ= Right upper quadrant of the abdomen, LFT= Liver function test, SIRS= Systemic inflammatory response syndrome, ERCP= Endoscopic retrograde cholangiopancreatography, N= Normal, AMA= Anti mitochondrial antibodies, LDH= Lactate dehydrogenase, GI= Gastrointestinal, CT= Computed tomography
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
References
- ↑ Escorsell A, Mas A, de la Mata M, Spanish Group for the Study of Acute Liver Failure (2007). “Acute liver failure in Spain: analysis of 267 cases”. Liver Transpl. 13 (10): 1389–95. doi:10.1002/lt.21119. PMID 17370334.
- ↑ Bower WA, Johns M, Margolis HS, Williams IT, Bell BP (2007). “Population-based surveillance for acute liver failure”. Am J Gastroenterol. 102 (11): 2459–63. doi:10.1111/j.1572-0241.2007.01388.x. PMID 17608778.
- ↑ Kumar R, Shalimar. Bhatia V, Khanal S, Sreenivas V, Gupta SD; et al. (2010). “Antituberculosis therapy-induced acute liver failure: magnitude, profile, prognosis, and predictors of outcome”. Hepatology. 51 (5): 1665–74. doi:10.1002/hep.23534. PMID 20196116.
- ↑ Lee WM, Stravitz RT, Larson AM (2012). “Introduction to the revised American Association for the Study of Liver Diseases Position Paper on acute liver failure 2011”. Hepatology. 55 (3): 965–7. doi:10.1002/hep.25551. PMC 3378702. PMID 22213561.
Epidemiology and Demographics
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Husnain Shaukat, M.D [2]
Overview
The incidence of acute liver failure in the United States is 2000-2300 cases annually. In the year 2009, the diagnosis of acute hepatic necrosis was 420 cases per 100,000 cases of all adult liver transplants in the United States. In the year 1998 to 2008, according to the United States acute liver failure (ALF) registry statistics, the most common cause of acute liver failure was acetaminophen with 46000 cases per 100,000 individuals and 12000 cases per 100,000 individuals for other drugs. Acute hepatitis B is the cause of acute liver failure in 1000 individuals per 100,000 individuals but it increases to 20,000 individuals per 100,000 individuals with hepatitis D virus co-infection. Acute liver failure is more common in women than men, and women with acute liver failure were older than men. Women are more commonly affected with autoimmune hepatitis and hepatitis E viral infection than men. The acute liver failure is seen more in the white population with 74,000 individuals per 100,000 individuals, 10,000 individuals per 100,000 individuals in the Hispanics, 3000 individuals per 100,000 individuals in the Black population and 5000 individuals per 100,000 individuals in the Asian population. The most common cause of acute liver failure in the developing countries is viral infection mainly hepatitis A and hepatitis B. The most common cause of acute liver failure in the developed world is acetaminophen toxicity. The acute liver failure secondary to hepatitis B is also on the rise in the developed world due to immigration.
Epidemiology and Demographics
- The incidence of acute liver failure in the United States is 2000-2300 cases annually.[1]
- In the year 2009, the diagnosis of acute hepatic necrosis was 420 cases per 100,000 cases of all adult liver transplants in the United States.[2]
- In the year 1998 to 2008, according to the United States acute liver failure (ALF) registry statistics, the most common cause of acute liver failure was acetaminophen with 46000 cases per 100,000 individuals and 12000 cases per 100,000 individuals for other drugs.[3]
- Acute hepatitis B is the cause of acute liver failure in 1000 individuals per 100,000 individuals but it increases to 20,000 individuals per 100,000 individuals with hepatitis D virus co-infection.[4]
Gender
- Women are more commonly affected with autoimmune hepatitis and hepatitis E viral infection than men.[5]
- Acute liver failure is more common in women than men and women with acute liver failure were older than men.
Race
- The acute liver failure is seen more in the white population with 74,000 individuals per 100,000 individuals, 10,000 individuals per 100,000 individuals in the Hispanics, 3000 individuals per 100,000 individuals in the Black population and 5000 individuals per 100,000 individuals in the Asian population.[5][6]
Developed Countries
- The most common cause of acute liver failure in the developed world is acetaminophen toxicity.[5]
- The acute liver failure secondary to hepatits B is also on the rise in the developed world due to immigration.
Developing Countries
- The most common cause of acute liver failure in the developing countries is viral infection mainly hepatitis A and hepatitis B.[5]
References
- ↑ Ichai P, Samuel D (2008). “Etiology and prognosis of fulminant hepatitis in adults”. Liver Transpl. 14 Suppl 2: S67–79. doi:10.1002/lt.21612. PMID 18825677.
- ↑ McDowell Torres D, Stevens RD, Gurakar A (2010). “Acute liver failure: a management challenge for the practicing gastroenterologist”. Gastroenterol Hepatol (N Y). 6 (7): 444–50. PMC 2933761. PMID 20827368.
- ↑ Stravitz RT, Kramer DJ (2009). “Management of acute liver failure”. Nat Rev Gastroenterol Hepatol. 6 (9): 542–53. doi:10.1038/nrgastro.2009.127. PMID 19652652.
- ↑ Shukla NB, Poles MA (2004). “Hepatitis B virus infection: co-infection with hepatitis C virus, hepatitis D virus, and human immunodeficiency virus”. Clin Liver Dis. 8 (2): 445–60, viii. PMID 15481349.
- ↑ 5.0 5.1 5.2 5.3 Wang FS, Fan JG, Zhang Z, Gao B, Wang HY (2014). “The global burden of liver disease: the major impact of China”. Hepatology. 60 (6): 2099–108. doi:10.1002/hep.27406. PMC 4867229. PMID 25164003.
- ↑ Larson AM, Polson J, Fontana RJ, Davern TJ, Lalani E, Hynan LS; et al. (2005). “Acetaminophen-induced acute liver failure: results of a United States multicenter, prospective study”. Hepatology. 42 (6): 1364–72. doi:10.1002/hep.20948. PMID 16317692.
Risk Factors
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Husnain Shaukat, M.D [2]
Overview
The risk factors in the development of acute liver failure can be categorized into viral, drugs and toxins, vascular, metabolic and systemic illnesses. Common risk factors of acute liver failure include acetaminophen toxicity, viral hepatitis (most commonly hepatitis A, hepatitis B and hepatitis E), alcoholic hepatitis, autoimmune hepatitis, sepsis, heart failure, renal failure, immunocompromised state, older age and malnourishment. Acetaminophen toxicity is the most common risk factor of acute liver failure in the developed world and viral hepatitis (most commonly hepatitis A, hepatitis B and hepatitis E) is most common in the developing world.
Risk Factors
Risk factors in the development of acute liver failure include:[1][2][3][4][2][5]
- Drug-related hepatotoxicity and idiosyncratic drug reactions are the most common risk factor in the developed world. The most common drug causing hepatotoxicity is acetaminophen.
- Viral hepatitis is the most common risk factor of acute liver failure in the developing world.
- Old age
- Malnourishment
- Vascular diseases
- Autoimmune disease
- Metabolic diseases
- Malignancy
- Primary liver tumor: Hepatocellular carcinoma
- Secondary liver tumor: Extensive hepatic metastases or infiltration from breast cancer, lung cancer, melanoma, lymphoma, leukemia.
- Long-term alcohol consumption
- Immunocompromised state
- Other systemic diseases
References
- ↑ Ichai P, Samuel D (2008). “Etiology and prognosis of fulminant hepatitis in adults”. Liver Transpl. 14 Suppl 2: S67–79. doi:10.1002/lt.21612. PMID 18825677.
- ↑ 2.0 2.1 Ostapowicz G, Fontana RJ, Schiødt FV, Larson A, Davern TJ, Han SH, McCashland TM, Shakil AO, Hay JE, Hynan L, Crippin JS, Blei AT, Samuel G, Reisch J, Lee WM (2002). “Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States”. Ann. Intern. Med. 137 (12): 947–54. PMID 12484709.
- ↑ Hoofnagle JH, Nelson KE, Purcell RH (2012). “Hepatitis E.” N Engl J Med. 367 (13): 1237–44. doi:10.1056/NEJMra1204512. PMID 23013075.
- ↑ Wasley A, Fiore A, Bell BP (2006). “Hepatitis A in the era of vaccination”. Epidemiol Rev. 28: 101–11. doi:10.1093/epirev/mxj012. PMID 16775039.
- ↑ Björnsson E, Olsson R (2005). “Outcome and prognostic markers in severe drug-induced liver disease”. Hepatology. 42 (2): 481–9. doi:10.1002/hep.20800. PMID 16025496.
Screening
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Husnain Shaukat, M.D [2]
Overview
There is insufficient evidence to recommend routine screening for an acute liver failure.
Screening
There is insufficient evidence to recommend routine screening for an acute liver failure.
References
Natural History, Complications and Prognosis
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Husnain Shaukat, M.D [2]
Overview
Acute liver failure is a sudden and severe loss of liver function with evidence of encephalopathy and coagulopathy with elevated prothrombin time (PT) and (INR) in a person without preexisting liver disease. The commonly used time duration for an acute liver disease is < 26 weeks. Acute liver failure can be hyperacute, acute or subacute depending upon how long the patient has signs and symptoms of liver failure. If left untreated, patients with acute liver failure can eventually progress to develop confusion, comatose state, and death. Common complications of acute liver failure are hepatic encephalopathy, cerebral edema, coagulopathy, a systemic inflammatory response syndrome, acute renal failure and acute pulmonary failure. The important factors in determining the prognosis of acute liver failure include patients’ age, the severity of encephalopathy and the underlying cause of acute liver failure. The commonly used prognostic indicators to predict mortality in patients with acute liver failure and to identify patients who are likely to benefit from liver transplantation include kings college criteria ( used for liver transplantation ) and model for end-stage liver disease (MELD) score (to predict mortality in patients with chronic and acute liver disease).
Natural History
Acute liver failure is a sudden and severe loss of liver function with evidence of encephalopathy and coagulopathy with elevated prothrombin time (PT) and (INR) in a person without preexisting liver disease. The commonly used time duration for an acute liver disease is < 26 weeks.[1]
- Acute liver failure can be hyperacute, acute or subacute depending upon how long the patient has signs and symptoms of liver failure.
- The natural history of acute liver failure depends on the etiology but generally, cerebral edema mainly presents in hyperacute or acute liver failure, whereas renal shutdown and portal hypertension are the main concerns in the subacute liver failure.
- If left untreated, patients with acute liver failure may initially having nonspecific symptoms such as anorexia, fatigue, nausea and vomiting, diffuse or right upper quadrant abdominal pain or jaundice and can eventually progress to develop confusion and the comatose state and death. A systemic inflammatory response syndrome may also develop. Acute renal failure occurs in up to 50% of cases. The condition can also worsen to the point of causing hemodynamic and cardiovascular compromise.
- The timely recognition and treatment of some of the causes of acute liver failure can reverse the condition and may improve the patient’s prognosis. The timely evaluation can also help in identifying patients who may require liver transplantation.
- In acetaminophen toxicity patients, the time duration between acetaminophen ingestion and treatment with acetylcysteine greatly influence the outcome.
Complications
Complications that can develop as a result of acute liver failure are:[2][3][4][5][6][7][8][9][10][11][12]
- Cerebral edema
- Encephalopathy
- Coagulopathy
- Renal failure
- Renal failure
- Systemic inflammatory response
- Metabolic derrangements
- Pulmonary complications
Prognosis
- The important factors in determining the prognosis of acute liver failure include patients’ age, the severity of encephalopathy and the underlying cause of acute liver failure.[13][14][15][16][17][18]
- Several prognostic scoring systems to predict mortality in patients with acute liver failure and to identify patients who are likely to benefit from liver transplantation include:
- King’s College Criteria (mostly used for liver transplantation)
- Model for End-Stage Liver Disease (MELD) score (used to predict mortality in patients with chronic and acute liver disease)
- Sequential Organ Failure Assessment (SOFA score)
- Clichy criteria
- Acute Liver Failure Study Group (ALFSG) index
References
- ↑ Bower WA, Johns M, Margolis HS, Williams IT, Bell BP (2007). “Population-based surveillance for acute liver failure”. Am J Gastroenterol. 102 (11): 2459–63. doi:10.1111/j.1572-0241.2007.01388.x. PMID 17608778.
- ↑ Kumar R, Shalimar. Bhatia V, Khanal S, Sreenivas V, Gupta SD; et al. (2010). “Antituberculosis therapy-induced acute liver failure: magnitude, profile, prognosis, and predictors of outcome”. Hepatology. 51 (5): 1665–74. doi:10.1002/hep.23534. PMID 20196116.
- ↑ Riordan SM, Williams R (1997). “Treatment of hepatic encephalopathy”. N. Engl. J. Med. 337 (7): 473–9. doi:10.1056/NEJM199708143370707. PMID 9250851.
- ↑ Lee WM (1993). “Acute liver failure”. N. Engl. J. Med. 329 (25): 1862–72. doi:10.1056/NEJM199312163292508. PMID 8305063.
- ↑ Muñoz SJ (1993). “Difficult management problems in fulminant hepatic failure”. Semin. Liver Dis. 13 (4): 395–413. PMID 8303321.
- ↑ Hazell AS, Butterworth RF (1999). “Hepatic encephalopathy: An update of pathophysiologic mechanisms”. Proc. Soc. Exp. Biol. Med. 222 (2): 99–112. PMID 10564534.
- ↑ Larsen FS, Wendon J (2002). “Brain edema in liver failure: basic physiologic principles and management”. Liver Transpl. 8 (11): 983–9. doi:10.1053/jlts.2002.35779. PMID 12424710.
- ↑ Armstrong IR, Pollok A, Lee A (1993). “Complications of intracranial pressure monitoring in fulminant hepatic failure”. Lancet. 341 (8846): 690–1. PMID 8095592.
- ↑ Schmidt LE, Larsen FS (2006). “hyperlactatemia“. Crit. Care Med. 34 (2): 337–43. PMID 16424712.
- ↑ Harry R, Auzinger G, Wendon J (2002). “The clinical importance of adrenal insufficiency in acute hepatic dysfunction”. Hepatology. 36 (2): 395–402. doi:10.1053/jhep.2002.34514. PMID 12143048.
- ↑ Bihari D, Gimson AE, Waterson M, Williams R (1985). “Tissue hypoxia during fulminant hepatic failure”. Crit. Care Med. 13 (12): 1034–9. PMID 3933911.
- ↑ Trewby PN, Warren R, Contini S; et al. (1978). “Incidence and pathophysiology of pulmonary edema in fulminant hepatic failure”. Gastroenterology. 74 (5 Pt 1): 859–65. PMID 346431.
- ↑ Dhiman RK, Seth AK, Jain S, Chawla YK, Dilawari JB (1998). “Prognostic evaluation of early indicators in fulminant hepatic failure by multivariate analysis”. Dig. Dis. Sci. 43 (6): 1311–6. PMID 9635624.
- ↑ Huo TI, Wu JC, Sheng WY, Chan CY, Hwang SJ, Chen TZ, Lee SD (1996). “Prognostic factor analysis of fulminant and subfulminant hepatic failure in an area endemic for hepatitis B”. J. Gastroenterol. Hepatol. 11 (6): 560–5. PMID 8792311.
- ↑ Takahashi Y, Kumada H, Shimizu M, Tanikawa K, Kumashiro R, Omata M, Ehata T, Tsuji T, Ukida M, Yasunaga M (1994). “A multicenter study on the prognosis of fulminant viral hepatitis: early prediction for liver transplantation”. Hepatology. 19 (5): 1065–71. PMID 8175127.
- ↑ Lake JR, Sussman NL (1995). “Determining prognosis in patients with fulminant hepatic failure: when you absolutely, positively have to know the answer”. Hepatology. 21 (3): 879–82. PMID 7875687.
- ↑ Pauwels A, Mostefa-Kara N, Florent C, Lévy VG (1993). “Emergency liver transplantation for acute liver failure. Evaluation of London and Clichy criteria”. J. Hepatol. 17 (1): 124–7. PMID 8445211.
- ↑ Rutherford A, King LY, Hynan LS, Vedvyas C, Lin W, Lee WM, Chung RT (2012). “Development of an accurate index for predicting outcomes of patients with acute liver failure”. Gastroenterology. 143 (5): 1237–43. doi:10.1053/j.gastro.2012.07.113. PMC 3480539. PMID 22885329.
Diagnosis
Diagnosis
Diagnostic Study of Choice | History and Symptoms | Physical Examination | Laboratory Findings | X Ray | CT | Ultrasound | Other Imaging Findings | Other Diagnostic Studies
Treatment
Treatment
Medical Therapy | Surgery | Primary Prevention | Secondary Prevention | Cost-Effectiveness of Therapy | Future or Investigational Therapies
Looking for the patient version?
© 2026 MyEClinic – IFTM Institut für Telematik in der Medizin GmbH
